Post-earnings recap
Reported
Thu, Jul 31, 2025
EPS actual
$0.32
EPS est.
$-0.75
EPS surprise
+142.90%
1-day move
+15.43%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a strong earnings surprise with an EPS of $0.32, significantly exceeding expectations. The stock reacted positively, rising by 15.43%, likely driven by investor confidence in the company's performance and future prospects. However, the lack of revenue data and guidance leaves some uncertainty about the overall financial health moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.32 | N/A | +142.90% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook on their recent achievements. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the strong EPS performance.
They highlighted ongoing efforts in research and development.
There was a focus on future growth opportunities.